Akèy › Kansè nan tete › Maryland › Baltimore
Etid klinik pou Kansè nan tete nan Baltimore, MD
47 etid pou Kansè nan tete ap chèche patisipan nan sit nan ak bò kote Baltimore (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
Ap rekriteFaz 3
- Mercy Medical Center, Baltimore
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
- Mercy Medical Center, Baltimore
- Sinai Hospital of Baltimore, Baltimore
- MedStar Franklin Square Medical Center/Weinberg Cancer Institute, Baltimore
- ak 2 plis
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Ap rekriteFaz 2
- Johns Hopkins University, Baltimore
Conventionally Fractionated vs. Hypofractionated Comprehensive Nodal Irradiation for Breast Cancer Using Pencil Beam Scanning Proton Therapy
Ap rekriteFaz 3
- Maryland Proton Treatment Center, Baltimore
Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer
Ap rekriteFaz 2
- Maryland Proton Treatment Center, Baltimore
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Ap rekriteFaz 3
- Mercy Medical Center - Baltimore ( Site 0015), Baltimore
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
Ap rekriteFaz 3
- Greenebaum Comprehensive Cancer Center ( Site 0036), Baltimore
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
Ap rekriteFaz 3
- Clinical Trial Site, Baltimore
- Clinical Trial Site, Baltimore
- Clinical Trial Site, Annapolis · 22 mi lwen
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
Ap rekriteFaz 1
- United Theranostics, Glen Burnie · 9 mi lwen
Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies
Ap rekriteFaz 2
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
Ap rekriteFaz 3
- Saint Agnes Hospital, Clinical Research Center, Baltimore
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Ap rekriteFaz 3
- Mercy Medical Center, Baltimore
- Ascension St. Agnes Hospital, Baltimore
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
Ap rekriteFaz 1/2
- Research Site, Baltimore
A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
Ap rekriteFaz 1/2
- Maryland Oncology Hematology - Annapolis, Annapolis · 22 mi lwen
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
Ap rekriteFaz 3
- Sidney Kimmel Comprehensive Cancer Center (SKCCC) at Johns Hopkins, Baltimore
Cardiometabolic Screening Program
Ap rekrite
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore
PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC
Ap rekriteFaz 2
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
Ap rekriteFaz 3
- University of Maryland, Baltimore
- Velocity Clinical Research, Annapolis · 22 mi lwen
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Ap rekriteFaz 3
- University of Maryland/Greenebaum Cancer Center, Baltimore
- Mercy Medical Center, Baltimore
- Greater Baltimore Medical Center, Baltimore
- ak 8 plis
A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases
Ap rekriteFaz 2
- The Johns Hopkins Sidney Kimmel Cancer Center, Johns Hopkins School of Medicine, Baltimore
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
Ap rekriteFaz 3
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
Ap rekriteFaz 2/3
- Local Institution - 1035, Baltimore
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
Ap rekriteFaz 3
- Maryland Oncology Hematology, Annapolis · 22 mi lwen
E-Mindfulness Approaches for Living After Breast Cancer
Ap rekriteFaz 3
- Maryland Proton Treatment Center, Baltimore
- University of Maryland/Greenebaum Cancer Center, Baltimore
- MedStar Franklin Square Medical Center/Weinberg Cancer Institute, Baltimore
- ak 7 plis
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
Ap rekriteFaz 2
- The John Hopkins Hospital, Baltimore
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
Ap rekriteFaz 2
- Sidney Kimmel Comprehensive Cancer Center, Baltimore
EXoPERT EMERALD Clinical Study
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
- John Hopkins University, Baltimore
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
Ap rekriteFaz 3
- Johns Hopkins Kimmel Cancer Center, Baltimore
CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer
Ap rekriteFaz 1
- Johns Hopkins University, Baltimore
Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
Ap rekriteFaz 1
- Advanced Molecular Imaging and Therapy, Glen Burnie · 9 mi lwen
- United Theranostics - Chesapeake, Glen Burnie · 9 mi lwen
Phase 1 Study of CLR 125 in Triple Negative Breast Cancer
Ap rekriteFaz 1
- United Theranostics, Glen Burnie · 9 mi lwen
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
Ap rekriteFaz 3
- Mfsmc-Hjwci, Baltimore
- Maryland Oncology Hematology P.A., Annapolis · 22 mi lwen
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
Ap rekriteFaz 3
- University of Maryland/Greenebaum Cancer Center, Baltimore
- Greater Baltimore Medical Center, Baltimore
- Saint Agnes Hospital, Baltimore
- ak 7 plis
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
Ap rekriteEtid obsèvasyon
- University of Maryland/Greenebaum Cancer Center, Baltimore
- Sinai Hospital of Baltimore, Baltimore
- UM Saint Joseph Medical Center, Towson · 8 mi lwen
- ak 1 plis
The Effects of Treating Insomnia on Behavioral Weight Loss Outcomes in Survivors of Breast Cancer
Ap rekrite
- Sidney Kimmel Comprehensive Cancer Center, the Avon Foundation Breast Center at Johns Hopkins, Baltimore
- Johns Hopkins Bayview, Baltimore
- Johns Hopkins Kimmel Cancer Center at Greenspring Station, Lutherville · 9 mi lwen
GammaPod Dose Escalation Radiation for Early Stage Breast Cancer
Ap rekrite
- UMMC, Baltimore
- Baltimore Washington Medical Center, Glen Burnie · 9 mi lwen
- Upper Chesapeake Health, Bel Air · 22 mi lwen
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
Ap rekriteFaz 1
- Johns Hopkins - Sidney Kimmel Comprehensive Cancer Center, Baltimore
EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)
Ap rekriteEtid obsèvasyon
- Weinberg Center at Mercy, Baltimore
- Greater Baltimore Medical Center, Baltimore
- Sinai Hospital of Baltimore, Baltimore
- ak 3 plis
Metabotyping of Broccoli Microgreen in Obese Breast Cancer Survivors
Ap rekrite
- Breast Evaluation and Treatment Program, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore
Study in Patients With Breast Cancer Leptomeningeal Metastasis
Ap rekriteEtid obsèvasyon
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Ap rekriteEtid obsèvasyon
- Massive Bio SYNERGY-AI site, Baltimore
- Massive Bio SYNERGY-AI site, Towson · 8 mi lwen
The Cancer of the Pancreas Screening-5 CAPS5)Study
Ap rekriteFaz 3
- Johns Hopkins Hospital, Baltimore
S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
Ap rekriteFaz 3
- UM Upper Chesapeake Medical Center, Bel Air · 22 mi lwen
MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles
Ap rekriteEtid obsèvasyon
- Mercy Medical Center, Baltimore
- Johns Hopkins Hospital, Baltimore
- Luminis Health Center for Cancer & Blood Disorders, Annapolis · 22 mi lwen
A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer
Ap rekriteFaz 2
- University of Maryland Medical Center (UMMC), Baltimore
A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies
Ap rekriteFaz 1/2
- Johns Hopkins, Baltimore
First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies
Ap rekriteFaz 1
- University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore
Etid Kansè nan tete nan lòt vil
- New York City, NY134 etid
- Houston, TX126 etid
- Boston, MA111 etid
- Nashville, TN80 etid
- Los Angeles, CA72 etid
- Edison, NJ68 etid
- St. Louis, MO64 etid
- Durham, NC63 etid
- Queens, NY63 etid
- Chicago, IL58 etid
- Philadelphia, PA56 etid
- Dallas, TX55 etid
Lòt etid nan Baltimore
- Kansè Poumon ki pa ti selil60 etid
- Kansè pwostat43 etid
- Kansè poumon40 etid
- Kansè (tout kalite)37 etid
- Kansè kolorektal31 etid
- Kansè pankreyas31 etid
- Kansè Metastatik28 etid
- Obèsite25 etid
- Ensifizyans kadyak24 etid
- Kansè vejik24 etid
- Akidan serebavaskilè22 etid
- Kansè ovè22 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.